SAN CARLOS, Calif. — Iovance Biotherapeutics, Inc., a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced a clinical program update for LN-145 TIL therapy in non-small lung cancer (NSCLC). The U.S. Food and Drug Administration (FDA) placed...
treatment News
SAN CARLOS, Calif. — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced interim data from its registrational Phase 2 IOV-LUN-202 trial of lifileucel monotherapy in patients with previously treated advanced...
PARIS – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that its New Drug Application (NDA) for palovarotene, an oral, investigational, selective RARγ agonist for the prevention of heterotopic ossification (new bone formation) as a potential treatment option for people living with the progressive disabling and ultra-rare genetic disorder fibrodysplasia ossificans progressiva...
PARIS, FRANCE, 19 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification (HO) in adults and children living with fibrodysplasia ossificans progressiva (FOP) vs. placebo, as a result the study will be...
Seven abstracts, including three late-breaking presentations, will be shared on new IQIRVO® (elafibranor) and Bylvay®/Kayfanda® (odevixibat) data, reinforcing the strong clinical value across Ipsen’s rare liver disease portfolio where unmet need is high and treatments are few In two late-breaking presentations, IQIRVO’s effect on fatigue and its relationship with pruritus in patients...
Paris, France – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval for Bylvay® (odevixibat) for the treatment of pruritus associated with progressive familial intrahepatic cholestasis (PFIC). PFIC is a group of rare genetic disorders in which bile acid accumulates in the...
WUHAN, China — iRegene Therapeutics Co., Ltd recently announced that NouvNeu001, the company’s first innovative product, has completed the dosing for its first patient at Beijing Hospital, and the patient has also successfully concluded the observation period. It is reported that the multicenter, open-label clinical trial (Phase I/II) is meticulously...
MOUNTAIN VIEW, Calif. — IRIDEX Corporation, headquartered in Mountain View, California, and Imperial College Healthcare NHS Trust in London, today announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse® Transscleral Laser Therapy (TLT) using Iridex’ Cyclo G6® Laser and...
GOTHENBURG, SWEDEN – IRLAB Therapeutics, a company discovering and developing novel treatments for Parkinson’s disease, today announced that the US FDA has granted an end-of-Phase 2 meeting for the mesdopetam program on February 20, 2024. “The end-of-Phase 2 meeting is an important milestone for the mesdopetam program. The further development...
BOSTON, Mass. – Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced positive topline results from its pivotal Phase III STARS trial, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in reducing parenteral support (PS) dependency in adult patients with short bowel syndrome with intestinal failure...